Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 505-510

  Jones, C Hal ^a   Tuckman, Margareta ^a   Howe, Anita Y M ^a   Orlowski, Mark ^a   Mullen, Stanley ^a   Chan, Karen ^a   Bradford, Patricia A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; MINOCYCLINE; OXACILLIN; TETRACYCLINE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EUROPE; GENE AMPLIFICATION; GENE IDENTIFICATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MECA GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RIBOSOME; SKIN INFECTION;

CLINICAL TRIALS, PHASE II; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMERASE CHAIN REACTION; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; TETRACYCLINE RESISTANCE;

EID: 31944447494     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.505-510.2006     Document Type: Article

References (55)

1. Anstead, G. M., and A. D. Owens. 2004. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr. Opin. Infect. Dis. 17:549-555.
2. Arbique, J., K. Forward, D. Haldane, and R. Davidson. 2001. Comparison of the Velogene Rapid MRSA identification assay, Denka MRSA-Screen assay, and BBL Crystal MRSA ID system for rapid identification of methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 40:5-10.
3. Bell, J. M., and J. D. Turnidge. 2002. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob. Agents Chemother. 46:879-881.
4. Biedenbach, D. J., M. L. Beach, and R. N. Jones. 2001. In vitro antimicrobial activity of GAR-936 tested against antibiotic resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 40:173-177.
5. Biedenbach, D. J., G. J. Moet, and R. N. Jones. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50:59-69.
6. Boucher, H. W., C. B. Wennersten, and G. M. Eliopoulos. 2000. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44:2225-2229.
7. Bouchillon, S. K., D. J. Hoban, B. M. Johnson, T. M. Stevens, M. J. Dowzicky, D. H. Wu, and P. A. Bradford. 2005. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn. Microbiol. Infect. Dis. 51:291-295.
8. Bouchillon, S. K., B. M. Johnson, D. J. Hoban, J. L. Johnson, M. J. Dowzicky, D. H. Wu, M. A. Visalli, and P. A. Bradford. 2004. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int. J. Antimicrob. Agents 24:119-124.
9. Bradford, P. A., P. J. Petersen, M. Young, C. H. Jones, M. Tischler, and J. O'Connell. 2005. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob. Agents Chemother. 49:3903-3909.
10. Bradford, P. A., D. T. Weaver-Sands, and P. J. Petersen. 2005. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5):S315-S332.
11. Breedt, J., J. Teras, J. Gardovskis, F. J. Maritz, T. Vaasna, D. P. Ross, M. Gioud-Paquet, N. Dartois, E. J. Ellis-Grosse, and E. Loh. 2005. Safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. 49:4658-4666.
12. Centers for Disease Control and Prevention. 2003. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31:481-498.
13. Chopra, I., and M. Roberts. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:232-260.
14. Clinical Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing: M100-S15, fifteenth informational supplement, vol. 25. Clinical Laboratory Standards Institute, Wayne, Pa.
15. Daum, R. S., T. Ito, K. Hiramatsu, F. Hussain, K. Mongkolrattanothai, M. Jamklang, and S. Boyle-Vavra. 2002. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J. Infect. Dis. 186:1344-1347.
16. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132.
17. Doern, G. V., R. N. Jones, M. A. Pfaller, K. C. Kugler, M. L. Beach, et al. 1999. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn. Microbiol. Infect. Dis. 34:65-72.
18. Fluit, A. C., A. Florijn, J. Verhoef, and D. Milatovic. 2005. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob. Agents Chemother. 49:1636-1638.
19. Fluit, A. C., M. E. Jones, F. J. Schmitz, J. Acar, R. Gupta, and J. Verhoef. 2000. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin. Infect. Dis. 30:454-460.
20. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.
21. Hardy, K. J., P. M. Hawkey, F. Gao, and B. A. Oppenheim. 2004. Methicillin resistant Staphylococcus aureus in the critically ill. Br. J. Anaesth. 92:121-130.
22. Hershow, R. C., W. F. Khayr, and P. C. Schreckenberger. 1998. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. Am. J. Ther. 5:213-220.
23. Hiramatsu, K. 1998. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104:7S-10S.
24. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
25. Holden, M. T., E. J. Feil, J. A. Lindsay, S. J. Peacock, N. P. Day, M. C. Enright, T. J. Foster, C. E. Moore, L. Hurst, R. Atkin, A. Barron, N. Bason, S. D. Bentley, C. Chillingworth, T. Chillingworth, C. Churcher, L. Clark, C. Corton, A. Cronin, J. Doggett, L. Dowd, T. Feltwell, Z. Hance, B. Harris, H. Hauser, S. Holroyd, K. Jagels, K. D. James, N. Lennard, A. Line, R. Mayes, S. Moule, K. Mungall, D. Ormond, M. A. Quail, E. Rabbinowitsch, K. Rutherford, M. Sanders, S. Sharp, M. Simmonds, K. Stevens, S. Whitehead, B. G. Barrell, B. G. Spratt, and J. Parkhill. 2004. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl. Acad. Sci. USA 101:9786-9791.
26. Jones, C. H., and P. J. Petersen. 2005. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs of Today 41:637-659.
27. Levy, S. B. 2001. Antibiotic resistance: consequences of inaction. Clin. Infect. Dis. 33(Suppl. 3):S124-S129.
28. Louie, L., S. O. Matsumura, E. Choi, M. Louie, and A. E. Simor. 2000. Evaluation of three rapid methods for detection of methicillin resistance in Staphylococcus aureus. J. Clin. Microbiol. 38:2170-2173.
29. Low, D. E., B. N. Kireiswirth, K. Weiss, and B. M. Willey. 2002. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int. J. Antimicrob. Agents 20:220-222.
30. Ma, X. X., T. Ito, C. Tiensasitorn, M. Jamklang, P. Chongtrakool, S. Boyle-Vavra, R. S. Daum, and K. Hiramatsu. 2002. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 46:1147-1152.
31. McAleese, F., E. Murphy, T. Babinchak, G. Singh, B. Said-Salim, B. Kreiswirth, P. M. Dunman, J. F. O'Connell, S. Projan, and P. A. Bradford. 2005. Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. Antimicrob. Agents Chemother. 49:4521-4529.
32. Milatovic, D., F.-J. Schmitz, J. Verhoef, and A. C. Fluit. 2003. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47:400-404.
33. Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.). 2003. Manual of clinical microbiology. 8th ed. ASM Press, Washington, DC.
34. NCCLS. 2003. Methods for dilution antimicrobial disk susceptibility tests; approved standards M2-A8, eighth ed., vol. 20. National Committee for Clinical Laboratory Standards, Wayne, Pa.
35. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A6. sixth ed., vol. 23. National Committee for Clinical Laboratory Standards, Wayne, Pa.
36. Nesin, M., P. Svec, J. R. Lupski, G. N. Godson, B. Kreiswirth, J. Kornblum, and S. J. Projan. 1990. Cloning and nucleotide sequence of a chromosomally encoded tetracycline resistance determinant, tetA(M), from a pathogenic, methicillin-resistant strain of Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2273-2276.
37. Nicola, F., C. Bantar, L. F. Canigia, S. Relloso, H. Bianchini, and J. Smayevsky. 2000. Comparison of several methods to determine methicillin- resistance in Staphylococcus aureus with focus on borderline strains. Diagn. Microbiol. Infect. Dis. 36:91-93.
38. Oliveira, D. C., and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2155-2161.
39. Petersen, P. J., and P. A. Bradford. 2005. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49:3910-3918.
40. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
41. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
42. Relman, D. A., T. M. Schmidt, R. P. MacDermott, and S. Falkow. 1992. Identification of the uncultured bacillus of Whipple's disease. N. Engl. J. Med. 327:293-301.
43. Rennie, R. P., R. N. Jones, and A. H. Mutnick. 2003. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45:287-293.
44. Reynolds, R., N. Potz, M. Colman, A. Williams, D. Livermore, A. MacGowan, and BSAC Extended Working Party on Bacteraemia Resistance Surveillance. 2004. Antimicrobial susceptibility of the pathogens of bacteraemia in the United Kingdom and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. 53:1018-1032.
45. Roberts, M. C. 2003. Tetracycline therapy: update. Clin. Infect. Dis. 36:462-467.
46. Rybak, M. J., and R. L. Akins. 2001. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 61:1-7.
47. Ryffel, C., W. Tesch, I. Birch-Machin, P. E. Reynolds, L. Barberis-Maino, F. H. Kayser, and B. Berger-Bachi. 1990. Sequence comparison of mecA genes isolated from methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Gene 94:137-138.
48. Sacchidanand, S., R. L. Penn, J. M. Embil, M. E. Campos, D. Curcio, E. Ellis-Grosse, E. Loh, and G. Rose. 2005. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized double-blind trial. Int. J. Infect. Dis. 9:251-261.
49. Sader, H. S., R. N. Jones, and J. B. Silva. 2002. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn. Microbiol. Infect. Dis. 44:281-288.
50. Schmitz, F. J., A. C. Fluit, S. Brisse, J. Verhoef, K. Kohrer, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.
51. Schmitz, F. J., A. Krey, R. Sadurski, J. Verhoef, D. Milatovic, and A. C. Fluit. 2001. Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J. Antimicrob. Chemother. 47:239-240.
52. Sum, P.-E., and P. Petersen. 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9:1459-1462.
53. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
54. Tiemersma, E. W., S. L. Bronzwaer, O. Lyytikainen, J. E. Degener, P. Schrijnemakers, N. Bruinsma, J. Monen, W. Witte, and H. Grundman. 2004. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg. Infect. Dis. 10:1627-1634.
55. Trzcinski, K., B. S. Cooper, W. Hryniewicz, and C. G. Dowson. 2000. Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 45:763-770.